{"id":"tedizolid-po","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Nausea"},{"rate":"3-8","effect":"Headache"},{"rate":"3-7","effect":"Diarrhea"},{"rate":"2-5","effect":"Vomiting"},{"rate":"1-3","effect":"Peripheral neuropathy"},{"rate":"1-2","effect":"Optic neuropathy"}]},"_chembl":{"chemblId":"CHEMBL2105669","moleculeType":"Small molecule","molecularWeight":"450.32"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tedizolid is an oxazolidinone antibiotic that binds to the bacterial 50S ribosomal subunit and inhibits peptidyl transferase, thereby blocking protein synthesis. It is bacteriostatic and has enhanced potency and improved pharmacokinetics compared to linezolid, its parent compound. Tedizolid demonstrates activity against gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and other resistant pathogens.","oneSentence":"Tedizolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:11:19.551Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute bacterial skin and skin structure infections (ABSSSI)"},{"name":"Community-acquired bacterial pneumonia (CABP)"}]},"trialDetails":[{"nctId":"NCT02444234","phase":"PHASE4","title":"Pharmacokinetics of Tedizolid Phosphate in Cystic Fibrosis","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2015-07","conditions":"Cystic Fibrosis","enrollment":11},{"nctId":"NCT02097043","phase":"PHASE1","title":"Phase I Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of DA-7218 in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2014-05","conditions":"Healthy","enrollment":31},{"nctId":"NCT01967225","phase":"PHASE3","title":"Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-11-23","conditions":"Skin Diseases, Infectious","enrollment":125}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Tedizolid PO","genericName":"Tedizolid PO","companyName":"University of Southern California","companyId":"university-of-southern-california","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tedizolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Used for Acute bacterial skin and skin structure infections (ABSSSI), Community-acquired bacterial pneumonia (CABP).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}